Increased mortality in toxic epidermal necrolysis with thalidomide: Corroborating or exonerating the pathogenetic role of TNF-α? [2]

British Journal of Dermatology

Volumn 155, Issue 4, 2006, Pages 842-843

  Namazi, M R ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; PENTOXIFYLLINE; PLACEBO; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR;

APHTHOUS ULCER; CYTOKINE PRODUCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MORTALITY; MOUTH ULCER; PATHOGENESIS; PRIORITY JOURNAL; TOXIC EPIDERMAL NECROLYSIS;

EPIDERMAL NECROLYSIS, TOXIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33748449483     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2006.07436.x     Document Type: Letter

References (6)

1. Chave TA, Mortimer NJ, Sladden MJ et al. Toxic epidermal necrolysis: current evidence, practical management and future directions. Br J Dermatol 2005; 153:241-53.
2. Wolkenstein P, Latarjet J, Roujeau JC et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998; 352:1586-9.
3. Jacobson JM, Greenspan JS, Spritzler J et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med 1997; 336:1487-93.
4. Nishimura K, Hashimoto Y, Iwasaki S. Enhancement of phorbol ester-induced production of TNF-α by thalidomide. Biochem Biophys Res Commun 1994; 199:455-60.
5. Redondo P, Ruiz De Erenchum F, Iglesias ME et al. Toxic epidermal necrolysis. Treatment with pentoxyfilline. Br J Dermatol 1994; 130:688-9.
6. Velez A, Moreno JC. Toxic epidermal necrolysis treated with N-acetylcysteine. J Am Acad Dermatol 2002; 46:469-70.